uploads/2018/06/Chart-04-2-1.jpg

Allergan’s US Specialized Therapeutics Segment

By

Updated

US Specialized Therapeutics

As discussed earlier, Allergan’s (AGN) US Specialized Therapeutics segment includes revenue from the US sales of specialized products, including eye care products, medical esthetics products, dermatology products, neuroscience products, and urology products.

The above chart compares the revenues for the US Specialized Therapeutics segment since the first quarter of 2017.

US Specialized Therapeutics revenue

The US Specialized Therapeutics segment reported revenue of $1.6 billion during the first quarter. The performances of US Specialized Therapeutics products during the quarter were as follows:

  • Eye care products reported an 11.2% decrease in YoY (year-over-year) revenue to $491.1 million during the first quarter. The decline was driven by lower sales of Restasis, Alphagan/Combigan, Lumigan/Ganfort, and eye drops, and it was partially offset by growth in Ozurdex sales.
  • US medical esthetics reported a 29.7% rise in YoY revenue to $635.6 million during the first quarter. This category included revenues from plastic surgery, regenerative medicines, facial esthetics, body contouring, and skincare products.
  • The plastic surgery franchise, including breast implants, reported revenue of $60.7 million during the first quarter.
  • Regenerative medicines, including Alloderm, Strattice, and other products, reported revenue of $128.2 million during the first quarter.
  • Facial esthetics products, including Botox products, Juvederm products, and Kybella, reported revenue of $327.7 million during the first quarter.
  • Body contouring products reported revenue of $87.1 million in the first quarter.
  • Skincare products, including Latisse products, reported revenue of $31.9 million during the first quarter.
  • The medical dermatology franchise reported a YoY fall in revenue to $54.0 million during the first quarter driven by lower sales of Aczone and Tazorac.
  • The neuroscience and urology franchise reported a 13.9% rise in YoY revenue of $381.3 million during the first quarter driven by increased sales of Botox therapeutic products.

The SPDR S&P Pharmaceuticals ETF (XPH) holds 4.5% in Allergan, 4.0% in Pfizer (PFE), 4.4% in Eli Lilly and Company (LLY), and 3.6% in Perrigo (PRGO).

More From Market Realist